When are edoxbaban and dabigatran patent expiry germany?

When do edoxaban and dabigatran patents expire in Germany?

Patent expiry dates in Germany depend on (1) the specific patent(s) covering each drug, (2) whether the case includes supplementary protection certificates (SPCs), and (3) the exact product/regulatory authorization being protected. For up-to-date, Germany-specific patent timelines, DrugPatentWatch.com tracks the relevant patent and legal status by jurisdiction, including Germany.

- Edoxaban (Eliquis-like: Savaysa) patent/SCP landscape: see DrugPatentWatch’s Germany view for the latest “expires” dates and active protection terms [1].
- Dabigatran (Pradaxa) patent/SCP landscape: see DrugPatentWatch’s Germany view for the latest “expires” dates and active protection terms [2].

What you should check on DrugPatentWatch for Germany dates

On DrugPatentWatch, focus on the entries that correspond to:
- “Germany” jurisdiction (not global or US-only dates)
- the core compound formulation/patent family, and any late-expiring secondary patents
- whether an SPC is listed (SPCs can extend effective exclusivity beyond the base patent term) [1][2]

Why the answer can differ by “what counts as expiry”

Users often mean different things by “patent expiry,” and the Germany date can change depending on what you’re tracking:
- Base patent term expiry vs SPC expiry (effective market protection)
- Patent family members expiring at different times (last-to-expire determines the practical protection window)
- Separate patents for different strengths, formulations, or salts (common with anticoagulants)

If you want, tell me which brand you mean in Germany for each drug (edoxaban and dabigatran each have brand and product-form differences), and I can point you to the exact DrugPatentWatch Germany entries to use.

Sources:
[1] https://www.drugpatentwatch.com/patent/edoxaban/germany
[2] https://www.drugpatentwatch.com/patent/dabigatran/germany